Drug Profile
Amphotericin B topical - DNDi/Humax Pharmaceutical/Universidad de Antioquia/PECET
Alternative Names: AnfoleishLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation; Humax Pharmaceutical; Universidad de Antioquia
- Developer Drugs for Neglected Diseases Initiative Foundation; Humax Pharmaceutical; Program for the Study and Control of Tropical Diseases; Universidad de Antioquia
- Class Antifungals; Antiprotozoals; Macrolides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cutaneous leishmaniasis
Most Recent Events
- 26 Jun 2019 No development reported - Phase-I/II for Cutaneous leishmaniasis in Colombia (Topical)
- 01 Jul 2016 DNDi completes a phase I/IIb trial in Cutaneous leishmaniasis in Colombia (NCT01845727)
- 18 Dec 2015 Phase-Ib/II development for Cutaneous leishmaniasis is ongoing in Colombia (NCT01845727)